American Diabetes Association’s 82nd Annual Scientific Sessions: #ADA2022


 

Coverage of the ADA Scientific Sessions is brought to you by the ADA x BT1 Collab.


From Friday, June 3rd to Tuesday, June 7th, 2022 the largest diabetes conference of the year— the American Diabetes Association’s 82nd Annual Scientific Sessions (#ADA2022)—is taking place. This annual meeting will bring together researchers, healthcare providers, diabetes technology companies and many more from around the globe.

Over the course of five days, more than 1,400 original research presentations and over 180 sessions on the latest advancements in research, treatment and care for people with diabetes will be shared.

As in previous years, the Beyond Type 1 team is attending the conference to share the newest research, treatments and care updates with our community. Tune in to Twitter for live coverage of key sessions. For our coverage for people with type 2 diabetes, click here.

News From ADA 2022

ADA2022

Year in Review: The Biggest News in Diabetes Clinical Science


Highlights from the last year of diabetes research and treatment include new biosimilar insulins and updated screening and diagnosis guidelines.MORE
ADA2022

The Future of Insulin — Will It Be Affordable for the People Who Need It?


Research is showing promising advancements with new weekly oral and injectable insulins—but will they actually be affordable?MORE
ADA2022

Diabetes + Dementia: Using Nasal Insulin to Improve Brain Function


With rising rates of obesity in both type 1 and type 2 diabetes, understanding the impact on long-term brain health and function is critical.MORE
ADA2022

Researchers Talk: Past, Present, and Future of Pancreas Transplants


Are pancreas transplants the way of the future for people with diabetes? Here’s what you should know about the procedure.MORE
ADA2022

Women + Exercise: It’s Complicated


Women living with type 1 diabetes are told exercise will help better manage their diabetes. That’s easier said than done. MORE
ADA2022

Young Adults with T1D + T2D Need Personalized Care


By understanding the unique challenges of early adulthood, providers can empower young adults with type 1 and type 2 diabetes.MORE
ADA2022

Reaching Everyone — Health Disparities in Physical Activity


People living with diabetes are told to just exercise more to better manage their diabetes. Here is why its not that simple. MORE
ADA2022

Another Reminder that Racial/Ethnic Inequality Exists in Diabetes Care


Despite the variety of diabetes medications and technology, race and ethnicity still weigh heavily on a person’s access to these life-saving tools.MORE
ADA2022

Race, Racism, and Diabetes Research


Diabetes care and research is still drastically impacted by racist practices. It’s time to call the racism out. MORE
ADA2022

Dexcom CEO Talks: Product Differences, Cost Expectations, and Mental Health


The CEO of Dexcom sat down with Beyond Type 1 at the American Diabetes Association’s 82nd Annual Scientific Sessions to talk all things G7.MORE
ADA2022

Challenges + Solutions for Underserved Communities in East Los Angeles


People living with diabetes in East L.A. face many challenges in getting the care they need. Is Blue Circle Health a potential solution?MORE
ADA2022

Addressing Social and Structural Health Inequities in Diabetes Care


To address long-standing health inequities, providers and health systems must engage with barriers to high-quality diabetes care.MORE
ADA2022

The Negative Impact of Diabetes Stigma: “Words create reality”


Key behavioral science research proves the impact of attitudes and words on people living with diabetes and why those stigmas must change.MORE
ADA2022

Weight Bias + Diabetes: “Stigma does not motivate anyone”


In this coverage, we share research highlighting how weight bias affects people with diabetes and what can be done to change public attitudes.MORE
ADA2022

Beta Cell Replacement Therapy: A Pathway to a Cure for Type 1 Diabetes?


Does beta cell replacement therapy present a pathway to a cure for T1D? Here’s what new research tells us about current limits and solutions.MORE
ADA2022

Mounjaro: Its Powerful Potential to Treat Type 2 Diabetes & Obesity


Experts discuss the impressive impact and future potential of using Mounjaro (tirzepatide) to treat obesity and type 2 diabetes.MORE
ADA2022

COVID-19 + Type 1 Diabetes: New Research Explores Possible Connections


These are the latest updates regarding the impact of COVID-19 on people with T1D and whether COVID-19 poses a risk for developing it.MORE
ADA2022

Research: Practical Use of Closed-Loop Insulin Pumps


Closed-loop insulin pump technology is a game-changer for those taking insulin. Here are essential tips to using them in day-to-day life.MORE
ADA2022

Access to Insulin: In the United States


Despite the growing variety of insulin and technology, access to this life-saving drug continues to be a dire problem in the United States.MORE
ADA2022

Access to Insulin: In Low-Income Countries


In many countries, a person with diabetes may walk for four days to get a vial of short-acting insulin and seven to 10 days for long-acting.MORE

WRITTEN BY Beyond Type 1 Editorial Team, POSTED 06/02/22, UPDATED 06/06/22

This piece was authored collaboratively by the Beyond Type 1 Editorial Team. This includes Liz Cambron-Kopco, Julia Flaherty, Lala Jackson, Julia Sclafani, T'ara Smith and Ginger Vieira.